Latest Thailand News

Kingsgate Consolidated updates its 2025 Mineral Resources and Ore Reserves, introducing a maiden estimate for the Chatree South-East Complex while reporting modest declines in overall Ore Reserves.

Kingsgate Consolidated has secured a six-week extension on the arbitral award deadline under the Thailand-Australia Free Trade Agreement, following political changes in Thailand including a new Prime Minister appointment.

JAYRIDE Group has inked a pivotal SaaS agreement with Thailand’s Drivemate, marking a strategic shift from airport transfers to a full-scale digital mobility platform. The partnership launches with a 2,000-vehicle pilot in Bangkok and aims for nationwide expansion within a year.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

JAYRIDE Group Limited has confirmed Randy Prado as CEO and Ram Navaratnam as Finance Director, cementing leadership as it advances its SaaS mobility platform with pilots in Southeast Asia.

My Rewards International Limited (ASX – MRI) has announced a pro rata non-renounceable entitlement offer aiming to raise up to $4.12 million, primarily to reduce debt and strengthen working capital. The offer is partially underwritten and open to shareholders in select countries, with key dates set for September and October 2025.

Kingsgate Consolidated reports a strong FY25 at its Chatree Gold Mine with 75,000 ounces produced and sets ambitious FY26 targets, while advancing its Chilean project.

InFocus Group Holdings has locked in up to AUD 1.7 million in potential revenues through new contracts in healthcare and logistics, underpinning its operational expansion in Southeast Asia.

Horizon Oil Limited reported robust FY25 financial and operational results at the RIU Good Oil & Gas Conference, highlighting sustained dividends and a clear growth strategy across its Asia-Pacific portfolio.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

VRX Silica Limited has obtained crucial works approval for its Arrowsmith North Silica Sand Project, paving the way for construction and operation ahead of targeted production in late 2026.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.